Directly halting the VEGF molecules released from the ischemic retina, intravitreal injection of anti-VEGF agents, either with bevacizumab (Avastin®; Genentech Inc.)or Ranibizumab (Lucentis®; Novartis), was demonstrated as effective in treating severe ROP and thus gained increasing popularity [8–11]. Here, VEGFA is linked to retinopathy of prematurity.